What Is Drawing Fresh Attention To Pharma Mar (BME:PHM)?

Pharma Mar (BME:PHM) just put fresh numbers on the table. For the nine months to September 30, 2026, the group reported net income of €8.7 million versus €15.32 million a year earlier.

Pharma Mar’s results land after a softer share price patch, with the stock down 6.24% on a 1 month share price basis and 16.58% over 3 months. However, the 3 year total shareholder return of 96.49% still points to a very different longer term story.

Scan Pharma Mar’s latest earnings against other potential opportunities by checking which companies make it into our 588 high quality undiscovered gems list today.

Bulls point to Pharma Mar’s long pipeline and discounted valuation signals, while bears focus on the recent drop in earnings and share price. Which story does the current valuation really support next?

Most Popular Narrative: 36% Undervalued

Pharma Mar’s most followed valuation story points to a fair value of €102.44 compared with the last close at €65.40. This frames the recent share price weakness very differently from the long term model the narrative sets out.

The recent approvals of Zepzelca in first-line maintenance small-cell lung cancer in the U.S. and Europe, together with early launch momentum and more than 50% growth in related U.S. royalties in H1 2026, point to a larger and more durable revenue base that many investors may not yet fully reflect in Pharma Mar’s valuation, with potential impact on both royalties and earnings.

See why 26 investors see Pharma Mar as 36% undervalued.

Result: Fair Value of €102.44 (UNDERVALUED)

Still, the Pharma Mar story can change quickly if competition bites harder into Zepzelca or Yondelis, or if key trials such as SALUO disappoint.

Find out about the key risks to this Pharma Mar narrative.

Next Steps

Sentiment around Pharma Mar is clearly mixed, with fresh earnings pressure set against a richer long term narrative. Act quickly, review the full picture, and weigh both concerns and opportunities by checking the 4 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Pharma Mar?

If you only watch Pharma Mar, you risk missing other opportunities that fit your style, your risk comfort, and your income goals.

• Target resilient performers with steady balance sheets by checking companies on our list of solid balance sheet and fundamentals (193 results).
• Hunt for mispriced quality by reviewing the stocks in our 224 high quality undervalued stocks.
• Build income potential into your portfolio by scanning the high yield options in our 232 dividend fortresses.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com